Phase 3 RESILIENT study of TNX-102 SL successfully demonstrated daily pain reduction over placebo (primary endpoint, p = 0.00005)
Continue reading here:
Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial...
Led by healthcare-focused institutional investors.
Originally posted here:
Tonix Pharmaceuticals Announces Registered Direct Offering of up to $144 Million
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients
More here:
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients
Anne-Marie Graffin is appointed as Chair of the Board of Directors
Follow this link:
Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors
CARBIOS has received €1.2M of the €11.4M granted by ADEME to further optimize its unique PET depolymerization process and guarantee its competitiveness
Read this article:
CARBIOS has received €1.2M of the €11.4M granted by ADEME to further optimize its unique PET depolymerization process and guarantee its...
TORONTO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the results of its annual general and special meeting of shareholders held Tuesday, December 19, 2023 (the “Meeting”) in Toronto, Ontario. All matters presented to the shareholders of the Company (the “Shareholders”) for approval as set out in the Company's Notice of Meeting and Information Circular, dated November 10, 2023 respectively, were approved by an overwhelming majority of votes cast at the Meeting. Of the 357,646,841 shares issued and outstanding on the record date for the Meeting, 143,297,862 shares, being 40% of the shares, were voted.
Read more here:
Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
Generative AI Poised to Reinvent Life Sciences, Leading to Profound Changes in Healthcare Generative AI Poised to Reinvent Life Sciences, Leading to Profound Changes in Healthcare
Read more from the original source:
Syneos Health Releases 2024 Health Trends
The rest is here:
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development...
ROSCREA, Ireland, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, announced today that it has completed a successful pre-Investigational New Drug (pre-IND) consultation with the U.S. Food and Drug Administration (U.S. FDA) to discuss development of naronapride for patients with proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease (PPI-nrsGERD). PPI-nrsGERD affects over 20 million patients in the U.S., and current treatments are focused solely on the mechanism of acid suppression without addressing gastrointestinal (GI) motility. Naronapride, Renexxion’s lead drug candidate, is a potential best-in-class oral, locally acting pan-GI prokinetic, which works by modulating two validated targets, 5-HT4 receptor agonism and D2 receptor antagonism, with a well-differentiated pharmaceutical, pharmacokinetics, safety, and efficacy profile from other 5-HT4 agonists.
Go here to read the rest:
Renexxion Ireland has Completed a Successful Pre-IND Consultation with the United States FDA for Development of Naronapride for Patients with...
MONT-SAINT-GUIBERT, Belgium, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency dated December 19, 2023, indicating that CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has crossed the statutory threshold of 55%, holding 29,358,654 voting rights, i.e. 58.37 % of Celyad Oncology’s voting rights.